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The CRISPR/Cas9 system is a powerful tool for studying gene function. Here, we describe
a method that allows temporal control of CRISPR/Cas9 activity based on conditional Cas9
destabilization. We demonstrate that fusing an FKBP12-derived destabilizing domain to Cas9
(DD-Cas9) enables conditional Cas9 expression and temporal control of gene editing in the
presence of an FKBP12 synthetic ligand. This system can be easily adapted to co-express,
from the same promoter, DD-Cas9 with any other gene of interest without co-modulation of
the latter. In particular, when co-expressed with inducible Cre-ERT2, our system enables
parallel, independent manipulation of alleles targeted by Cas9 and traditional recombinase
with single-cell speciﬁcity. We anticipate this platform will be used for the systematic
characterization and identiﬁcation of essential genes, as well as the investigation of the
interactions between functional genes.
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T
emporal, spatial and locus-speciﬁc control of gene
expression is essential for understanding gene function
in biological systems. While ectopic expression of
complementary DNAs (cDNAs) has been possible for several
decades, the ablation of gene expression has been more
problematic. The use of conditional alleles under the control
of engineered recombinases, as well as antisense and RNAi-
mediated gene silencing, have enabled gene knock-down in vitro,
as well as in vivo with varying degrees of success1–3. More
recently, new genome-editing methods, such as zinc-ﬁnger
nucleases (ZFNs), transcription activator-like nucleases
(TALENs) and Clustered, regularly interspaced, short
palindromic repeats and the Cas9 endonuclease (CRISPR/Cas9),
have been shown to be powerful tools for directly mutating
the genome through targeted gene deletions4–6. In the case
of CRISPR/Cas9, the Cas9 nuclease is directed to speciﬁc
DNA sequences by an engineered small guide RNA (sgRNA)6.
The resulting cleavage sites are repaired by non-homologous
end-joining, with the consequent introduction of random
mutations into the targeted gene and functional inactivation of
genes at high-frequency6. This system has proven to be both
efﬁcient and robust across a variety of genetic contexts7,8.
One of the main problems limiting the use of current CRISPR
methods is the constitutive endonuclease activity when Cas9 and
its sgRNA are co-expressed. This can be particularly problematic
when targeting genes that are developmentally important or
essential for viability. Furthermore, it has been shown that
constitutive expression of Cas9 can increase the number of
off-target mutations and can trigger a DNA damage response9,10.
Hence, we sought to improve on existing CRISPR/Cas9
techniques to generate a system that (1) would provide potent,
robust and temporally controlled gene editing, (2) be applicable
to a broad spectrum of cell types and tissues, (3) facilitate high-
throughput manipulation and (4) be traceble.
To this end, we exploited a recently developed strategy in
which a cell-permeable ligand is used in conjugation with a single
genetically encoded destabilizing domain (DD) to regulate the
expression of any protein of interest11. While the addition of
a DD-tag to a protein partner results in proteasomal degradation
of the entire fusion product, treatment with a high-afﬁnity ligand
stabilized the DD-domain and the fusion protein as a whole in
a dose-dependent manner12. This approach enables ligand-
mediated control of protein stability and function in a highly
speciﬁc, reversible and dose-dependent manner.
The ﬁrst DD technology was developed based on the
identiﬁcation of speciﬁc destabilizing mutations in the human
FKBP12 protein, and the development of a family of highly
speciﬁc synthetic FKBP12 ligands that are highly cell permeable
and nontoxic in cultured cells and animals11. The small-molecule
ligand Shield-1 was shown to bind to mutant FKBP12 more
tightly than to wild type by three orders of magnitude13 and to
prevent proteasome-induced degradation of DD-GFP and other
fusion proteins14. This destabilized-domain system has been
demonstrated to work well for a variety of proteins including
kinases, cell cycle regulatory proteins and small GTPases
expressed in cultured cells, as well as in mice11,15.
By fusing the FKBP12-derived destabilizing domain to Cas9
(that is, DD-Cas9) we demonstrated that this method of
conditional regulation of protein stability could be exploited
for rapid and reversible Cas9 expression in vitro.
In particular we showed that this new method could be used to
conditionally target a variety of genes controlling diverse
biological processes such as oncogenic transformation (EGFR),
DNA damage responses (TP53), mitochondria metabolism
(CypD) and DNA replication/repair (RPA3). By targeting the
RPA3 gene and EGFR in ‘EGFR-addicted’ cells we demonstrated
the ability of DD-Cas9 system to identify genes that are essential
for sustained cell growth and survival.
One important aspect of this method that makes it unique is
the conditional regulation of Cas9 protein expression indepen-
dently of its messenger RNA (mRNA) expression. Hence,
this vector system can be easily adapted to co-express, from the
same promoter, DD-Cas9 with any other gene of interest, without
the latter being co-modulated. We demonstrated this approach
could be used for generating traceable systems and for
interrogating genes functional interactions in vivo.
Moreover, when DD-Cas9 is coupled with a conditional
Cre allele (Cre-ERT2), this system could be utilized to facilitate
the analysis of genes that modulate disease onset and progression
in a variety of pre-existing mouse models of human disease based
on Cre-Lox system.
In summary, our data indicate that fusing Cas9 to
a destabilizing domain provides a highly efﬁcient and easily
scalable new modality for temporal control of gene editing that
can be applicable to a broad spectrum of in vitro and in vivo
models.
Results
Controlled Cas9 expression by destabilized domain fusion.
CRISPR/Cas9 technology has been widely utilized to create
heritable changes in the genome. However, mutations often result
in cell lethality, functional deﬁcits and developmental defects,
limiting the utility of such models for studying gene function. In
addition, constitutive expression of Cas9 may result in toxicity
and in the generation of off-target effects16.
To overcome these limitations, we generated a temporally-
controlled Cas9 expression system by fusing Cas9 to an
engineered mutant of the human FKBP12 protein (DD-Cas9).
Previous studies demonstrated that the presence of this
destabilizing peptide induces the rapid degradation of the
fused-protein by the proteasome system11. Yet, in the presence
of a synthetic ligand (Shield-1), the peptide and the fusion partner
are effectively ‘shielded’ from degradation (Fig. 1a). To this end,
we developed a dual lentiviral vector system consisting of
a ﬁrst module, in which the sgRNA cassette is driven by the
constitutive U6 promoter, and the second, in which Cas9 is
fused at its N-terminus with a ligand-responsive destabilizing
domain derived from an engineered FKBP12 mutant (DD-Cas9)
under the control of the elongation factor-1a short (that is, EFS)
promoter (Fig. 1b).
To test for the feasibility of this approach, we transduced our
engineered lentiviral construct into A549 cells and we measured
the levels of Cas9 in the presence and absence of Shield-1 by
western blot and RT-PCR analyses (Fig. 1c). Antibodies against
Flag were used to gauge Cas9 levels indirectly. Although Cas9 was
not detected in uninfected cells or in lysates of mock-treated
cells, cells treated with Shield-1 showed strong expression of
the expected fusion protein in a dose-dependent manner.
Importantly, all experimental conditions presented with similar
levels of expression of Cas9 mRNA in the presence or absence of
synthetic ligand (Fig. 1c).
We next assayed the destabilizing domain for the kinetics of
protein degradation. Cells were treated with Shield-1 and
harvested 2, 6, 12, 24, 48 and 72 h after ligand treatment. On
just 2 h of treatment with Shield-1, we observed a rapid induction
of Cas9 protein expression compared with uninfected and
mock-control cells (Fig. 1d). This effect was reversible on 2 h of
ligand withdrawal from the media, with protein levels becoming
negligible within 12 h (Fig. 1d). The fact that Cas9 was not
detectable in mock-control cells or on Shield-1 withdrawal
indicates that the fusion of Cas9 with the engineered FKBP12
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destabilized mutant holds Cas9 expression under tight control
(Fig. 1d).
Taken together, these data demonstrated that, when fused
to Cas9, FKBP12-derived destabilizing domains enable tight,
rapid and reversible control of Cas9 expression, making DD-Cas9
a suitable tool for the generation of inducible genome editing
systems.
Temporal control of gene editing by destabilized Cas9. To
assess whether destabilized Cas9 (DD-Cas9) was competent
for gene editing we targeted multiple genes controlling diverse
biological processes such as oncogenic transformation (EGFR),
DNA damage responses (TP53), mitochondria metabolism
(CypD) and DNA replication/repair (RPA3). A549 cells
were transduced with lentiviral constructs expressing DD-Cas9
and locus-speciﬁc guide RNAs (Supplementary Fig. 1). Cells
were treated with ligand 24 h after lentiviral infection. At
that point, cell extracts were collected after 6 days and immu-
noblotted to verify gene editing (Fig. 2a; Supplementary Fig. 2).
The efﬁcient formation of on-target insertion/deletion (in-dels)
mutations in cells treated with Shield-1 was conﬁrmed via the
SURVEYOR assay (Fig. 2b) and in the case of TP53 by deep
sequencing (Fig. 2c–e; Supplementary Fig. 3). Data analysis
indicated that induction of Cas9 with Shield-1 led to efﬁcient
gene editing, and resulted in a signiﬁcant reduction in the
expression of EGFR, CypD, RPA3 and p53 proteins.
Notably, a comparison between inducible DD-Cas9 and
constitutive Cas9 also indicated similar levels of efﬁciency of
gene editing (Fig. 2d,e; Supplementary Fig. 3).
Next, to test whether DD-Cas9 could be used to functionally
characterize genes in vitro and in vivo, we targeted the essential
RPA complex. RPA is the heterotrimeric single-stranded
DNA binding complex composed of the RPA1, 2 and 3 proteins,
which stabilizes replication forks by coating unwound DNA17,18.
The RPA complex also binds single stranded DNA (ssDNA) at
sites of DNA damage and recruits cell cycle checkpoint
kinases18,19. Previous work showed that targeting the smallest
RPA subunit, RPA3, induces degradation of all three members
of the RPA complex, and is associated with decreased
cell proliferation and increased cell lethality20,21. Hence we
chose to target the RPA3 locus to assess the competency of
our system to study genes that are required for cell survival.
A549 cells were transduced with lentiviral constructs
expressing DD-Cas9 and two independent RPA3 sgRNAs
(RPA3 g.25 and g.44), as well as with Renilla sgRNA (g.208)
used as control transduction (Supplementary Fig. 1). In the
absence of Shield-1, we did not observe difference in number of
cells between uninfected cells and cells infected with lentiviruses
targeting RPA3 or Renilla (Fig. 3a,c). Yet, on treatment with
Shield-1, a drastic decrease in cell number was apparent in
cells infected with the lentivirus harbouring the RPA3 but not
the Renilla guide (Fig. 3a). Consistent with our previous
data (Figs 1 and 2), analysis of the onset of this effect indicated
that just 48 h exposure to Shield-1 compound was sufﬁcient
to induce robust decreases in cell viability (Supplementary Fig. 4).
We previously showed that the Non-Small Cell Lung Cancer
derived PC9 cells harbor an oncogenic-EGFR mutation and
are highly dependent on EGFR for their survival, as opposed
to the case of EGFR wild-type cells such as A549 cells22. We took
advantage of this observation to test whether DD-Cas9 could be
used for the identiﬁcation of genotype-driven vulnerabilities. PC9
cells were transduced with lentiviral constructs carrying the guide
RNAs targeting the EGFR locus (EGFR g.10 and g.60) (Supple-
mentary Fig. 1). As shown by the crystal violet staining and cell
counting, treatment of PC9 cells with Shield-1 resulted in a
prominent and rapid decrease of viable cells (Fig. 3b,d). This was
not observed for A549 cells transduced with constructs targeting
Renilla or the EGFR locus, albeit western blot analysis of cell
extracts conﬁrmed decreased expression of EGFR in these cells.
Shield-1 compound has been shown to be not toxic and to
have good pharmacodynamics and kinetic properties in mice
models11. Having shown ligand-dependent gene knockout in
in vitro cell culture, we reasoned that this platform could be
exploited for assessing gene function in vivo as well. As a proof of
principle, we transplanted A549 cells transduced with the
DD-Cas9 vector targeting either RPA3 or Renilla into immune-
compromised mice via sub-cutaneous injection (Fig. 3e). When
tumours reached an approximate size of 4–5mm in diameter,
mice were treated with Shield-1 or vehicle for 4 days and tumour
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Figure 1 | Establishment of an inducible lentiviral guide RNA expression
system based on conditionally destabilized Cas9. (a) Diagram of
conditionally destabilized Cas9 (DD-Cas9). Cas9 is fused to the
destabilizing domain of mutant FKBP12 that triggers the rapid degradation
of the fused-protein. The synthetic ligand (Shield-1) prevents this
destabilizing effect and prevents Cas9 from degradation. Note, a Flag-tag is
present at the C-terminal of Cas9. (b) Schematic of the lentiviral construct
utilized in our studies. (c) Ligand-dependent stabilization of DD-Cas9. Cells
expressing destabilized Cas9 (DD-Cas9) and uninfected cells (NI) were
either mock-treated (vehicle) or treated with increasing concentrations of
Shield-1 as indicated. To measure level of expression of Cas9, lysates were
analysed by Western blot with an anti-Flag antibody. Various degrees of
Shield-1-induced stabilization could be observed in a dose-dependent
manner. DD-Cas9 was not detected in lysate from mock-treated cells. To
verify that the destabilization of DD-Cas9 occurs post-transcriptionally,
DD-Cas9 expression was also veriﬁed by RT-PCR analysis using Cas9
speciﬁc primers and GAPDH as loading control. (d) Rapid and reversible
regulation of destabilized DD-Cas9. A549 cells transduced with the
DD-Cas9 lentiviral vector and uninfected cells were treated with Shield-1
(200nM) for different time points as indicated. Samples were assayed by
western blot analysis at the indicated time points.
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size was assessed for the next 10 days. We observed a drastic
decrease in tumour growth in tumours expressing RPA3 sgRNA
on Shield-1 treatment (Fig. 3f,g). Immuno-staining conﬁrmed
decreased RPA3 protein expression in tumour cells infected with
RPA3 sgRNA on Shield-1 treatment (Supplementary Fig. 5).
Design of a traceable system based on destabilized Cas9. An
additional advantage of this system is the conditional regulation
of Cas9 protein stability independently of its mRNA expression.
This implies that any gene of interest can be co-expressed with
destabilized Cas9 from the same promoter. Among various
Vehicle b
c e
d
a
Ren
Ren
Ren
Ren
TP53 Locus
1 2 3 4 5 6 7 8
PAM
DD-Cas9
D
D
-C
as
9
D
D
-C
as
9
80%
60%
40%
20%
0%
Ve
hic
le
Ve
hic
le
Re
nill
a
Renilla
Tp
53
 g.
14
0
Tp53 g.140
Sh
ield
-1D
2
Sh
ield
-1D
6
Sh
ield
-1D
4
Sh
ield
-1D
6
Cas9
Ca
s9
Ca
s9
Target 1 (20bp)
9 10 11 100%
TP53 g.140
50%
0%
100%
100%
100%
50%
50%
50%
50%
50%
50%
50%
0%
0%
0%
0%
0%
0%
0%
0 50 100 150
Breakpoint span (bp) Deletion (bp) Insertion (bp)
Breakpoint span (bp) Deletion (bp) Insertion (bp)
200 250 0 5 10 0 5 10
Renilla g.208
0 50 100 150 200 250 0 5 10 0 5 10
100%
100%
100%
3’
3’
5’
Exon
5’
5’
3’
Ren
α-EGFR
α-CypD
α-RPA3
α-p53
α-tubulin
α-tubulin
α-tubulin
α-tubulin
g.10
g.131
g.25
g.140 Ren g.140
180 kDa
55 kDa
55 kDa
55 kDa
55 kDa
53 kDa
15 kDa
25 kDa
g.44 Ren g.25 g.44
g.131g.150 g.150
g.60 Ren g.10 g.60
Shield-1 Vehicle
Ren g.10 g.60 Ren g.10
44.2
44.0
41.4 43.4
52.1
53.6
45.8 Indel (%)
Indel (%)
Indel (%)
Indel (%)
g.60
Shield-1
Vehicle
Vehicle
Shield-1
Ren Reng.131 g.131g.150 g.150
Vehicle Shield-1
Shield-1
Ren g.25 g.44 Ren g.25 g.44
Vehicle Shield-1
Vehicle Shield-1
Ren g.140 Ren g.140
Vehicle
Ve
hi
cl
e
Ve
hi
cl
e
Shield-1
Sh
ie
ld
-1
da
y 
2
Sh
ie
ld
-1
da
y 
4
Sh
ie
ld
-1
da
y 
6
Sh
ie
ld
-1
da
y 
6
1,000 bp
100 bp
500 bp
100 bp
500 bp
1,000 bp
100 bp
1,000 bp
500 bp
300 bp
500 bp
1,000 bp
In
de
l f
ra
ct
io
n
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14370
4 NATURE COMMUNICATIONS | 8:14370 | DOI: 10.1038/ncomms14370 |www.nature.com/naturecommunications
strategies employed to construct bi-cistronic or multi-cistronic
vectors, an internal ribosomal entry site (IRES) has been
widely used. More recently, a self-cleaving 2A peptide has
been shown to be an alternative strategy. As a proof of principle
to verify the possibility of expressing a gene of interest
together with conditionally destabilized Cas9, we cloned the
ﬂuorescent protein Venus downstream of DD-Cas9 and separated
them with the self-cleaving 2A peptide (P2A) (Fig. 4a). As
shown in Fig. 4b, expression of the modiﬁed-GFP ﬂuorescent
protein (Venus) was constitutively expressed despite fusion
to DD-Cas9, and was not altered by Shield-1 treatment.
Similarly, the mRNA expression was independent of ligand
treatment (Fig. 4b).
An important consideration when developing therapeutic
strategies based on decreased expression of a gene by viral
delivery is the potential impact on the physiology and viability of
the transduced cells. This effect can be particularly relevant
in longer time course experiments, where subtle differences in
cell growth rates can have a major impact.
In this regard, ‘competition assays’ have been shown to
be powerful systems to be able to score for subtle cell
growth changes23. This assay is based on the competitive
cell growth between transduced and non-transduced cells24.
The mixed culture obtained after gene transduction can
be observed in the ratio of Venusþ and Venus cells over
time to identify minor cell growth defects25. When compared
with established methods of counting cells and viability
assays (for example, MTT and ATP bioluminescence),
competition assays were demonstrated to provide superior
sensitivity.
To verify that our platform could also be used in competition
assay set-up, we infected A549 cells with the DD-Cas9/P2A/
Venus lentiviral vectors targeting either RPA3 or, as a negative
control, the Renilla gene at low MOI. This ensured the generation
of Venusþ and Venus mixed culture (Fig. 4c). By tracking
the ratio of Venusþ and Venus cells infected with the
RPA3-targeting vector on a time-course of 12 days, we observed
a Shield-1-dependent depletion of Venusþ cells (Fig. 4c,d).
The newly developed 3D ‘organoid’ culture system allows
for cultivation of both normal and patient-derived primary
tumours in vitro26. We tested whether the DD-Cas9/P2A/Venus
platform could also be applicable to this culture system
(Fig. 4e; Supplementary Fig. 6). On infection, we observed
approximately 80% Venusþ organoids. Strikingly in organoids
derived from two different tumours, after treatment with Shield-1
this fraction decreased to o20% for the RPA3-targeting sgRNA
(Fig. 4f; Supplementary Fig. 7). This result clearly demonstrates
the utility and efﬁciency of the DD-Cas9 system as a screening
tool in primary tumour cells. Although, further experiments
(that is, independent sgRNAs) will be required to validate RPA3
as a gene that is essential for primary pancreatic cells growth
and/or survival.
DD-Cas9 linked to Cre allows genetic interactions studies.
Recent studies indicated that a CRISPR/Cas9-based approach
could be used for the functional investigation of candidate
genes in well-established mouse models of cancer27,28. In
particular, these studies showed that Cre-dependent somatic
activation of oncogenic Kras (G12D) could be combined with
CRISPR/Cas9-mediated genome editing of tumour suppressor
genes by using a lentiviral-based system that delivers both the
CRISPR/Cas9 system and the CRE recombinase29.
We reasoned that by generating a bi-cistronic vector for the
expression of destabilized Cas9 and tamoxifen-inducible Cre, we
could uncouple gene editing and Cre-mediated recombination. By
providing temporal control of gene editing and activation/
inactivation of LOX alleles, this approach will enable a more
precise study of the functional interactions among genes in a
variety of pre-existing mouse models derived from Cre-Lox
system. Especially in the context of cancer models, it could be
used to dissect more precisely the role of mutations identiﬁed in
onco-genomic studies during tumour onset and progression. In
particular, given that cancer is a multi-step process that involves
the progressive accumulation of mutations, this approach could
be invaluable for the identiﬁcation of tumour-cell vulnerabilities
during the evolution of tumours from pre-neoplastic to fully
malignant diseases.
To achieve this, we engineered the DD-Cas9/P2A/Venus
backbone to express Cre-ERT2 downstream of Cas9 (Fig. 5a).
More speciﬁcally, we inserted an internal ribosome entry site
(IRES) downstream of DD-Cas9 open reading frame (ORF),
which was then coupled to tamoxifen inducible Cre (Cre-ERT2).
In this setting, gene editing could be induced independent of
Cre-mediated recombination.
To test this system, we used genetically engineered mouse
lines that express the ﬂuorescent reporter protein tdTomato
in a Cre-dependent manner from the constitutive CAG promoter
(tdTomLSL; Ai14). In this setting, following Cre-mediated
deletion of the ﬂoxed stop cassette, tdTomato can be readily
expressed. We derived mouse embryonic ﬁbroblasts (MEF) and
transduced them with our lentiviral vector. Three days after
infection, MEFs were acutely treated with 4-hydroxytamoxifen to
induce activation of Cre (Fig. 5b). We assessed expression of
tdTomato by ﬂuorescent microscopy and FACS. TdTomato
positive cells were readily observed only in MEFs infected
with DD-Cas9/IRES/Cre-ERT2 on 4-hydroxytamoxifen treatment
(Fig. 5c).
Next, to assess the gene editing efﬁciency of our system, we
targeted the Cre-activated tdTomato knock-in reporter allele
with lentiviruses expressing sgRNAs against tdTomato (sgTom)
or Renilla as control. When we quantiﬁed sgRNA-transduced
tdTomato positive MEF cells over time, we observed a substantial
reduction in tdTomato expression only in those cells treated
with Shield-1 compound (Fig. 5d). Thus, this result suggests
that the unique system which we have developed is a functional
Figure 2 | Validation of DD-Cas9 system with multiple methods for gene editing efﬁciency and comparison with constitutive Cas9. (a) Targeting of
EGFR, CypD, TP53 and RPA3 genes in human A549 cells by DD-Cas9. A549 cells transduced with DD-Cas9 lentiviral vector harbouring sgRNAs targeting the
indicating genes. See Supplementary Fig. 1 for further information. Western blot analysis was used to assess the expression of the indicated genes before
and after treatment with Shield-1 (200 nM). Alpha-tubulin was used as a loading control. Protein expression analysis was conducted following 3 days of
Shield-1 treatment. (b) Representative SURVEYOR assays for DD-Cas9–mediated on-target indels generation at the human EFGR, TP53, CypD and RPA3 loci
in the presence and absence of Shield-1. DNA extracts were prepared similar to what was described for the above described protein expression analysis.
Arrowheads indicate expected SURVEYOR fragments. (c) Schematic of location of small guide RNA on the TP53 locus utilized in our study. (d) Insertion/
deletion efﬁciencies. Shown is the percentage of reconstructed sequences in each sample that differ in length from the wild type sequence. Note that this
count excludes Cas9-edited sequences that have an insertion and deletion of the same length. (e) Insertion/deletion summary statistics. Summary
statistics for each sample are shown. Left-most plots show the fraction of sequences in which each nucleotide position was edited, either through a deletion
spanning that base or through an adjacent insertion. Middle plots report the fraction of sequences having a deletion of the speciﬁed length. Right plots
report the fraction of sequences having an insertion of the speciﬁed length. Note that individual sequences can have both an insertion and a deletion.
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tool for gene editing of an endogenous allele and that Cre and
Cas9 activity could be uncoupled.
In summary, these results demonstrate for the ﬁrst time
the potential of using destabilizing domain technology to generate
a highly scalable and efﬁcient platform for the temporal control
of CRISPR/Cas9 based gene editing. Importantly, this study
presents a novel approach to test for cooperativity between
genetic events and to identify tumour cell vulnerabilities in
in vitro and in vivo models.
Discussion
The possibility of acutely inactivating genes in cells and in
organisms is essential to understand gene function. Lethality is
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the most conclusive phenotype deﬁning a gene as essential. In the
context of cancer research, essential genes are of particular
interest as they could provide potential therapeutic targets. Yet,
the fact that on their inactivation the cells die renders them the
most difﬁcult class of genes to study.
Many different approaches have been developed and used in
the past for the identiﬁcation and characterization of essential
genes. These methods include the generation of temperature-
sensitive mutants30, conditional deletion alleles in which a gene of
interest is ﬂanked by loxP recombination sites to enable acute
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gene inactivation on expression of Cre recombinase31, and
inducible gene knockdown based on shRNA mediated
silencing32. More recently, methods to temporally control
CRISPR/Cas9 based genome editing technology have also been
developed. These systems are based on DOX-induced sgRNA
and Cas9 expression, the intein or on a split Cas9 system that
relies on rapamycin treatment or blue light exposure for the
formation of a holo-Cas9 enzyme33–37.
As an alternative to these existing CRISPR/Cas9 techniques we
utilized a conditionally destabilized Cas9. By exploiting a strategy
developed by the Wandless lab, we showed that by conjugating
a genetically encoded destabilizing domain to Cas9 we could
achieve a highly speciﬁc-conditional regulation of Cas9 expres-
sion and gene editing. Compared with other methods33–37,
this approach enables the generation of a system that (1) provides
potent, robust and temporally controlled gene editing,
(2) is applicable to a broad spectrum of cell types and tissues,
(3) facilitates high-throughput manipulation and (4) can be
traceable.
As the small-molecule DD ligand Shield-1 is highly permeable
and nontoxic in cultured cells and animals, we also demonstrated
our methods could be utilized in transplantable model system
and in mice mosaic models. In particular, by coupling DD-Cas9
with tamoxifen-inducible Cre, we showed that our lentiviral
vector could, in principle, facilitate the study of genetic
interaction in vivo in a variety of pre-existing mouse models of
human diseases based on the Cre-lox system.
Recent studies have shown that a similar lentiviral vector based
on tandem expression of Cas9 and Cre recombinase could be
used in vivo to rapidly evaluate human cancer genome
candidates38. Our approach enables temporal and independent
control of gene editing and of Cre-mediated recombination.
Hence, in principle this method uniquely enables the
investigation of the role of putative cancer genes in tumour
onset, progression and in driving tumours vulnerabilities.
In summary, our work demonstrates that the use of
a conditionally-destabilized Cas9 could be harnessed for the
temporal control of gene editing. This novel platform is very
robust and easily scalable and, therefore, is suitable for the
identiﬁcation and/or characterization of essential genes and
the interrogation of gene functional interaction in vitro and
in vivo.
Methods
Animals. All animal experiments were performed in accordance with National
Research Council’s Guide for the Care and Use of Laboratory Animals. Protocols
were approved by the Cold Spring Harbor Laboratory animal care and use
committee. Six-week old male NU/NU mice were purchased from Charles River.
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A549 lung cancer cells were plated, and infected in vitro with lentiviruses
carrying Renilla or RPA3 sgRNAs at a multiplicity of infection (MOI) of o1.
Xenograft tumours of A549 cells with inducible-Cas9 expression were established
in the ﬂanks of mice by subcutaneous injection of 5 105 cells in 200ml volume
mixed with 1:1 dilution basement membrane matrix with biological activity
(Matrigel, BD Biosciences). Five to six mice per each group were used in each
experiment. Tumours were allowed to grow for 2 weeks. When tumours reached
a palpable size, mice were randomly segregated into cohorts that received either
four times (once every day) local peritumoral injection of Shield-1 (1 mg diluted in
100ml PBS) or vehicle placebo on a course of four days. Tumour growth was
followed for ten days using a vernier caliper (volume¼ ((dshort)2 (dlong))/2).
At the end of the experiment, mice were killed. Tumours were extracted and ﬁxed
in freshly prepared 4% paraformaldehyde for 24 h.
Cell lines. All cell lines were obtained from American Type Culture Collection.
A549 and PC9 cells were cultured in RPMI supplemented with 5% Fetal Bovine
Serum (FBS, HyClone) and 100Uml 1 penicillin and 100mgml 1 streptomycin
(Gibco) at 37 C with 5% CO2 incubation. MEFs and Hek-293T cells were
maintained in Dulbecco’s Modiﬁed Eagles Medium (DMEM) with 10% FBS and
antibiotics. Virus packaging was achieved by transiently co-transfecting Hek-293T
cells on 10 cm culture dish with 3 mg of the construct encoding the genes of interest
and sgRNA along with 6 mg of the packaging plasmid psPAX2 and 3 mg of the
envelope plasmid pMD2.G (Addgene) using 30 ml of the Lipofectamine 2000
reagent (Life Technologies). Viral particles of10ml were collected after 48 h of
transfection by clarifying the supernatant through 0.45 mm ﬁlter membrane
(GE Healthcare). Virus transduction was optimized in order to achieve low
MOI transduction. Typically, 500ml fresh virus particles from 10ml stock were
used to infect 1 106 cells on a 10 cm culture dish in 10ml total volume of culture
medium. Virus aliquots were stored at  80 C. Shield-1, obtained from
Cheminpharma, was solubilized in pure ethanol, and was added to culture media
with given concentrations.
Organoids. Methods to establish and propagate human organoids cultures were
previously described30. Organoid infections were performed as described above. In
brief, organoids were grown into a 24-well culture plate for two days before
infection. One well per infection was used. The day of infection, organoids
were dissociated into small fragments by ﬁrst triturating them in media through
a ﬁre-polished glass pipette, and then by a 5-min enzymatic digestion with
TrypLE (Life Technologies) at 37 C. The resulting small cell clusters were then
resuspended with low MOI lentivirus and spinoculated at 600 RCF for 1 h at room
temperature.
Plasmids. Vectors used in this study were engineered based on the LentiCRISPR
V2 (Addgene) backbone. P2A-linked puromycin located downstream of the
SpCas9 was substituted with P2A-linked Venus, a modiﬁed version of Green
Fluorescent Protein (GFP) for easy visualization of viral transduction efﬁciency as
well as competition assays. To do so, P2A-Puro-WPRE-30LTR cassette on the
LentiCRISPR V2 was excised with BamHI/PmeI restriction enzymes, then
a PCR product containing only WPRE-30LTR piece was re-ligated which was again
surrounded by BamHI/PmeI. Following this step, a PCR product containing the
P2A-Venus cassette surrounded by BamHI digestion sites on both ends was
ampliﬁed and cloned into the BamHI site on the plasmid in the correct orientation.
High-afﬁnity ligand dependent destabilization domain (DD) of a mutant
FKBP12 protein (F36V, L106P) was inserted at the N-terminus of SpCas9. The
DD sequence was ampliﬁed from Degron-donor backbone (pMK backbone),
kindly provided by Frank Stegmeier. BsmBI digestion site in the DD-sequence was
replaced with silent mutations by site-directed mutagenesis. Similarly, Cre-ERT2
backbone was generated by introducing a stop codon at the end of the Cas9 ORF,
and cloning IRES and Cre-ERT2 ORFs downstream of Cas9 cassette with NLS and
Flag-tag. Here, Cre-ERT2 protein codon was optimized for human expression with
three naturally existing BsmBI restriction enzyme sites removed by silent mutations
was synthesized, cloned into pUC57 cloning vector and sequence veriﬁed by
Genscript. This vector served as a template for subsequent cloning experiments.
IRES sequence was PCR-ampliﬁed from TTI-GFP backbone (from Scott Lowe
laboratory). All PCR-based ampliﬁcations of cloning templates were performed
with Phusion High Fidelity DNA Polymerase (M0530, New England Biolabs).
Primers used in cloning procedures are listed in Supplementary Table 4. The
sequences of different sgRNAs used in this study are listed in Supplementary
Table 1.
Western blot. Protein samples were isolated by resuspending cell pellets in RIPA
buffer (50mM Tris–HCl at pH 7.6, 150mM NaCl, 1% NP-40, 0.5% Na deox-
ycholate, 0.1% SDS). After removal of the debris, samples were quantiﬁed with
colorimetric BCA kit (Pierce). 20 mg total proteins were electrophoresed on
6–12% gradient gels and wet-transferred to nitrocellulose membranes. After 1 h
blocking with 5% nonfat dry milk in 1 TBS, 0.1% Tween20 at room temperature,
membranes were incubated with antibodies diluted in 2% w/v BSA as follows; Flag
[M2] mouse mAb (1:1000, Sigma) to detect DD-SpCas9 expression, a-tubulin
[DM1A] mouse mAb (1:20,000, Millipore) as equal loading control, GFP [C163]
mouse mAb (1:5,000, Thermo Fisher) to detect Venus expression, p53 [DO-1]
mouse mAb (1:1,000, Millipore), CypD [E11AE12BD4] mouse mAb (1:5,000,
Abcam), RPA14 [11.1] mouse mAb (1:1,000, Abcam), EGFR [1F4] mouse mAb
(1:1,000, Cell Signaling Technology) and DD monoclonal Ab (1:1,000, Clontech).
All incubations were performed overnight at 4 C. Membranes were rinsed
thoroughly with 1 TBS-T and then incubated with species-speciﬁc ﬂuorescently
labelled secondary antibodies (1:5,000, LICOR). Western blots were eventually
imaged on near-IR ﬂuorescence scanner (Odyssey Imaging System, LICOR).
RNA isolation and RT-PCR. Cells were rinsed twice and harvested with ice cold
PBS. Pellets were lysed in 1ml Trizol (Invitrogen) and RNA was extracted
according to the manufacturer’s instructions. Contaminating DNA was removed
by RNase-free DNase (Promega) treatment for 30min at 37 C. cDNA was
prepared from 2 mg total RNA using ImProm-II Reverse Transcription System
(Promega) with 16mer oligo(dT). Semi-quantitative RT-PCR detection was
performed using Taq DNA Polymerase with standard Taq buffer (NEB) using
primers speciﬁc to SpCas9, GFP and GAPDH. Primers used for RT-PCR analysis
are listed in Supplementary Table 2.
Surveyor assay. Cells were infected with lentivirus and incubated at 37 C for
indicated times as described. Genomic DNA was extracted using mini-spin
columns following the manufacturer’s instructions (Macherey–Nagel). In brief,
cell pellets were re-suspended in Lysis Buffer and incubated at 56 C for 3 h and
70 C for 10min. SpCas9-induced mutations were detected using the SURVEYOR
Mutation Detection Kit (Transgenomic/IDT). Approximately 900 bp region
surrounding the CRISPR mutation target site was PCR-ampliﬁed using Phusion
High-Fidelity DNA Polymerase (NEB). Single band PCR products were puriﬁed
using USB PrepEase Gel Extraction kit (Affymetrix). 450 ng puriﬁed PCR frag-
ments mixed with 2 ml 10 Taq DNA Polymerase PCR buffer in a total volume of
20 ml were subjected to a series of melt and reanneal temperature cycles with
gradual increments lowered in each thermal cycle. SURVEYOR nuclease and
SURVEYOR enhancer were then added to the reaction mixture in order to
selectively digest heteroduplex DNA substrates. Digested products were run
and visualized on a 1.2% agarose gel. Band intensities were quantiﬁed using
ImageJ software. Indel percentage was calculated using the formula
100 (1 (1 (bþ c)/(aþ bþ c))1/2), where a stands for the integrated intensity
of the undigested product and b and c are the integrated intensities of each cleaved
PCR product. Primers used for Surveyor assay are listed in Supplementary Table 3.
Crystal violet staining. Cells infected with lentiviruses were plated in equal
number in 12 well plates (BD falcon) with expression of Cas9 stabilized using
200 nM of Shield-1 and incubated at 37 C for indicated times as described.
Cells were rinsed twice with PBS to eliminate the ﬂoating cells and ﬁxed in
4% Formaldehyde in PBS (V/V) for 10–15min. Fixed cells were stained by staining
solution (0.1% Crystal violet in 10% ethanol) for 20min. Staining solution was
aspirated from the wells and cells were washed with water thrice in order to remove
extra stain. Stained cells were air dried and imaged using Odyssey Imaging
System (LICOR). To quantify the relative cell numbers, cells were destained
with 10% Acetic acid and absorbance of de-stained solution was measured at
590 nm at appropriate dilutions.
Miseq library construction. Target region primers (F-CCTGGTCCTCTGA
CTGCTCT, R-CTGCCCTGGTAGGTTTTCTG) surrounding the TP53 guide
RNA (gRNA.140) recognition site were designed using the batch version of
Primer3. The genomic locus was ampliﬁed with Phusion High-Fidelity
DNA Polymerase (NEB) using 100 ng genomic DNA as input and 20-cycles of
PCR. Amplicons were puriﬁed using Nucleospin Gel and PCR Clean-up
(Macherey–Nagel). Sequencing libraries were prepared using the NEBNext Ultra
DNA Library Preparation kit for Illumina (cat# E7370), strictly following the
manufacturer’s instructions. Brieﬂy, 50 ng of input template was end-repaired,
tagged with Illumina adaptors and treated with USER enzyme, followed by limited-
cycle PCR with indexing primers. After this ampliﬁcation, DNA was puriﬁed
with Agencourt AMPure XP beads (Beckman Coulter). Then, barcoded libraries
were pooled in equimolar ratios, quantiﬁed by a qPCR library quantiﬁcation
kit (KAPA Biosystems) and subjected to massively parallel 150-bp pair-end
sequencing using Miseq Instrument with Miseq Reagent 300 Cycles Kit
v2 (Illumina).
Sequence analysis. Illumina reads were processed as previously described39, with
minor modiﬁcations. To summarize, paired forward and reverse Illumina reads
were stitched together if they overlapped by at least 15 bp in their 30 ends, and
contained at least 40 bp of wild-type sequence in their 50 ends. These ‘observed
sequences’ were then aligned with the wild-type sequence starting from both ends
and moving inward. Forward and reverse breakpoints were deﬁned for each
observed sequence as positions where the aligned wild-type sequence and observed
sequence ﬁrst began to differ by at least two consecutive mismatches. The region of
wild-type sequence between these breakpoints was deﬁned as the ‘deletion’, and the
region of observed sequence between these breakpoints was deﬁned as the
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‘insertion’. Figure 2e illustrates a pileup of the observed deletion sequences and
provides a histogram showing the lengths of the insertion and deletion regions39.
Supplementary Fig. 8 shows an alignment of the 20 most frequently observed
patterns near the Cas9 target sequence, as well as counts of these patterns for each
of the eight samples. For each observed sequence, this alignment shows the region
upstream of the forward breakpoint and downstream of the reverse breakpoint, as
well as the inserted sequence (if any). Some observed sequences had very long
insertions, and the length of these inserted sequences is indicated in brackets. These
long insertions usually came paired with long deletions, a phenomenon that likely
represents an artifact of the breakpoint calling algorithm arising from a region of
low sequence quality in the reverse reads. This artifact, however, does not affect the
conclusions drawn from this dataset.
Data availability. The sequence data associated with this study has been deposited
into the NCBI Sequence Read Archive with accession number SRP078612.
Processed data and analysis scripts are available at https://github.com/jbkinney/
15_sordella. The authors declare that all other data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles or
from the corresponding author on request.
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